BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12097278)

  • 21. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma.
    Afify AM; Werness BA; Mark HF
    Exp Mol Pathol; 1999 Jun; 66(2):163-9. PubMed ID: 10409445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.
    Simonetti S; Russo R; Ciancia G; Altieri V; De Rosa G; Insabato L
    Int J Surg Pathol; 2009 Jun; 17(3):198-205. PubMed ID: 19443884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
    Latta EK; Tjan S; Parkes RK; O'Malley FP
    Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma.
    Koka V; Potti A; Koch M; Fraiman G; Mehdi S; Levitt R
    Anticancer Res; 2002; 22(3):1593-7. PubMed ID: 12168842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coexpression of EGFR and HER-2 in pancreatic ductal adenocarcinoma: a comparative study using immunohistochemistry correlated with gene amplification by fluorescencent in situ hybridization.
    Dancer J; Takei H; Ro JY; Lowery-Nordberg M
    Oncol Rep; 2007 Jul; 18(1):151-5. PubMed ID: 17549361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification and relationship of HER-2/neu overexpression to short-term mortality in primary malignant brain tumors.
    Forseen SE; Potti A; Koka V; Koch M; Fraiman G; Levitt R
    Anticancer Res; 2002; 22(3):1599-602. PubMed ID: 12168843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switching off HER-2/neu in a tetracycline-controlled mouse tumor model leads to apoptosis and tumor-size-dependent remission.
    Schiffer IB; Gebhard S; Heimerdinger CK; Heling A; Hast J; Wollscheid U; Seliger B; Tanner B; Gilbert S; Beckers T; Baasner S; Brenner W; Spangenberg C; Prawitt D; Trost T; Schreiber WG; Zabel B; Thelen M; Lehr HA; Oesch F; Hengstler JG
    Cancer Res; 2003 Nov; 63(21):7221-31. PubMed ID: 14612517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of breast cancer according to the status of HER-2/neu oncogene amplification.
    Huang WY; Newman B; Millikan RC; Conway K; Hulka BS; Schell MJ; Liu ET
    Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):65-71. PubMed ID: 10667465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
    Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P
    Breast J; 2005; 11(4):278-80. PubMed ID: 15982396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
    Prati R; Apple SK; He J; Gornbein JA; Chang HR
    Breast J; 2005; 11(6):433-9. PubMed ID: 16297088
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
    Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
    Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry.
    Pellegrini C; Falleni M; Marchetti A; Cassani B; Miozzo M; Buttitta F; Roncalli M; Coggi G; Bosari S
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3645-52. PubMed ID: 14506153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
    Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
    Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors?
    Underwood M; Bartlett J; Reeves J; Gardiner DS; Scott R; Cooke T
    Cancer Res; 1995 Jun; 55(11):2422-30. PubMed ID: 7757996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
    J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HER-2 gene amplification in Paget disease of the nipple and extramammary site: a chromogenic in situ hybridization study.
    Bianco MK; Vasef MA
    Diagn Mol Pathol; 2006 Sep; 15(3):131-5. PubMed ID: 16932067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative analysis of the EGF-receptor family in pancreatic cancer: expression of HER-4 correlates with a favourable tumor stage.
    Thybusch-Bernhardt A; Beckmann S; Juhl H
    Int J Surg Investig; 2001; 2(5):393-400. PubMed ID: 12678544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical relevance of HER-2/neu expression in germ-cell testicular tumors.
    Mándoky L; Géczi L; Bodrogi I; Tóth J; Csuka O; Kásler M; Bak M
    Anticancer Res; 2004; 24(4):2219-24. PubMed ID: 15330164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing.
    Schmidt M; Lewark B; Kohlschmidt N; Glawatz C; Steiner E; Tanner B; Pilch H; Weikel W; Kölbl H; Lehr HA
    Breast Cancer Res; 2005; 7(2):R256-66. PubMed ID: 15743506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of HER-2/neu status by real-time quantitative PCR in malignant cartilaginous tumors.
    Park HR; Kim YW; Jung WW; Kim HS; Unni KK; Park YK
    Int J Oncol; 2004 Mar; 24(3):575-80. PubMed ID: 14767542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.